Purpose-built for physicians Semaglutide linked to reduced risk for Alzheimers in patients with diabetes Key takeaways: Semaglutide was associated with a 40% to 70% lower risk for AD diagnosis within 3 years vs
If symptoms suggest a new endocrine problem, baseline testing is reasonable before starting therapy, with a follow-up check at three months for the standard panels: HbA1c, fasting glucose, TSH, and free T4 if on thyroid therapy, morning cortisol only when clinically indicated, and sex hormones if symptoms arise
Despite inherent limitations of observational data and potential for residual confounding, the results from these observational analyses support, in line with RCT findings, combining SGLT2is and GLP-1RAs to reduce cardiovascular events in patients with diabetes in routine clinical care [12, 23, 43, 63]
GLP-1 injections can have a similar impact for people who historically struggle to maintain a healthy relationship with food